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Even with newer and repurposed anti-TB drugs almost a third of patients with XDR-TB have 
unfavourable outcomes. In patients with localised disease and adequate pulmonary reserve, 
surgery is an important adjunctive treatment. However, there are no outcome data from TB 
endemic countries, and the prognostic significance of pre-operative PET-CT findings remains 
unknown. 
Objectives: 
To report outcomes for resectional surgery in our setting, and to study whether PET activity 
outside of the resection influences treatment outcomes. 
Methods: 
A retrospective study of all XDR-TB patients undergoing surgery at Groote Schuur Hospital 
(GSH) between July 2010 and December 2016 was performed. PET-CT was performed in a 
subgroup. Patients were followed up to determine treatment outcomes at 24-months post- 
surgery. Treatment success and failure, including all-cause mortality, was determined. 
Results: 
In total, 35 patients underwent surgery. The mean age was 36, 49% were male and 26% 
were HIV-infected. Pneumonectomy was the most common procedure (57%). Three patients 
(9%) were lost to follow up by 24 months. Total all-cause mortality was 34%. Treatment 
success was achieved in 15/35 (43%). In patients who underwent pre-operative PET-CT, 
there were no overall radiological features or PET parameters that were found to be 
prognostic for treatment failure. 
Conclusion: 
Resectional surgery for DR-TB in combination with chemotherapy resulted in cure in less than 
half of patients. Our data do not support the use of PET-CT to preselect patients or 
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prognosticate about their outcome. These data inform clinical practice and underscore the 
need to support antibiotic stewardship strategies in TB-endemic settings. 
[Word count: 250] 
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Background of drug resistant Tuberculosis 
Pre-XDR and XDR-TB are public health emergencies in South Africa with limited 
pharmacological options for cure. The overall treatment outcomes of pre-XDR and XDR-TB 
in South Africa are far from satisfactory (1). A retrospective review (in the era before new and 
repurposed drugs) showed that only 19% of patients culture-convert on currently available 
therapy (2). In the absence of readily accessible and effective drug regimens, and in 
appropriate patients, surgery with resection of involved lung tissue is employed as a form of 
adjunctive treatment. Even with the development and approval of the novel anti-tuberculous 
agents bedaquiline and delaminid, which have shown good success, the overall cure rates 
for drug- resistant TB still remain well below those of drug-sensitive disease (3-6). 
Furthermore, accessibility to these drugs still remains challenging in parts of South Africa. 
These dismal cure rates, ranging from 11-19% with medical therapy alone for XDR-TB are 
comparable to those for drug-sensitive TB in the earlier half of the 20th century when 
effective anti-tuberculous drugs were not yet available (2, 7). During this time, surgical 
resections were commonplace and formed an important part of therapy. Over the past 
century, surgical techniques have developed and improved dramatically and the old 
techniques of collapsotherapy and thoracoplasty have been largely replaced by anatomical 
resections in the form of lobectomies or pneumonectomies. 
Rationale for resectional surgery 
The rationale behind surgery for TB is to dramatically reduce the overall organism burden in 
the lung by excising thick-walled cavitatory lesions and areas of destroyed lung. This involves 
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the removal of sites with highest concentrations of drug resistant bacilli, as we know that 




M.tb organisms, which is exponentially higher than in 
areas of non-cavitatory parenchymal disease (8). These cavitatory areas have been shown to 
act as reservoirs where mycobacterial replication can proceed with significant protection from 
the effects of anti-tuberculous drugs (9). This “debulking” hopes to enhance the sterilizing 
properties of post-surgical chemotherapy and increase the likelihood of treatment success (10, 
11). In appropriate patients with localized disease and adequate pulmonary reserve, surgery is 
an important adjunctive part of management. 
Indications for surgical resection 
The two most commonly accepted indications for surgical intervention in drug-resistant TB 
are: 
• Patients who have failed medical therapy and remain persistently sputum culture positive 
• Patients who are sputum culture negative, but have established localised cavitatory disease 
that may serve as an ongoing nidus for infection. 
The vast majority of patients undergoing surgery fell into the first category of failed medical 
therapy, defined as failure to induce a sustained sputum-negative culture conversion (12-14). 
This was consistent throughout the literature, with only few patients having been operated on 
with persistent cavitatory, sputum-negative disease. The role for surgery in patients who 
remain sputum culture-negative with localised cavitatory disease is slightly less well defined. 
The rationale for resection in sputum culture-negative patients is the belief that antibiotic 
therapy penetration into thick-walled cavities is poor and that there remains a high burden of 
viable bacilli within these cavities, putting patients at high risk of relapse and treatment 
failure (8, 15). 
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The general consensus between many international reviews and studies seems to be that 
adjunctive surgical management, in appropriately selected patients, is superior to medical 
therapy alone in cases of all forms of drug-resistant tuberculosis. This will be explored in 
further detail by this review of current literature. 
Definition and utility of PET/CT 
Positron emission tomography-computer tomography (PET/CT) is a nuclear medicine 
technique, which combines both the PET and CT modalities into a single test to produce 
images in which the two results are superimposed. 
PET imaging uses radiotracers, which are molecules labelled with small amounts of 
radioactive material, that can be detected by PET scan. The most commonly used tracer is 
F- 18 fluorodeoxyglucose (FDG) which is taken up more by tissues with higher metabolic 
activity. CT scanners use radiation to produce detailed anatomical images of the region of 
interest. PET/CT therefore produces a combination of both the functionality, as measured by 
FDG uptake, and anatomy of a given area. This technique has been used widely in the field 
of oncology to determine the extent of disease, as well as the response to treatment, as 
many cancers have higher metabolic demands than their surrounding tissue. 
The utility of PET/CT in detection and evaluation of response to treatment in tuberculosis has 
not been as wide spread as in oncology. Current literature seems to suggest that PET/CT is 
a sensitive tool to both detect TB and differentiate between active TB and previous infection 
especially in cases with cavitatory disease (16). It has also been shown that PET/CT is 
superior to CT or MRI alone in detecting active tuberculous disease (17). Given that areas 
with active TB have a higher metabolic activity than surrounding tissues, a few studies have 
proposed use of PET/CT as a modality to detect early responses to anti-tuberculous 
treatment, but no definitive guidelines have been drawn as yet (18). Little is known about the 
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role of PET/CT as a prognostic tool to predict treatment outcomes in patients with pulmonary 
TB. 
LITERATURE REVIEW OBJECTIVES 
Firstly, this literature review shall present the current state of evidence of what is known 
about outcomes of resectional surgery for drug resistant TB in other centres, with an 
emphasis on pre-XDR and XDR-TB. Alongside detailing the outcomes of resectional surgery, 
we will also explore the rationale and timing for surgery in these patients. The duration of 
post-operative medical treatment will also be described where possible. We also seek to 
describe whether there are any known patient or treatment characteristics that predict 
treatment outcomes in settings similar to our own. 
Secondly, we shall review whether PET-CT has been used for prognostic purposes in 
patients undergoing resectional surgery for drug-resistant TB. If such data does exist, we will 
describe the role of PET-CT as a modality to predict treatment outcomes. 
LITERATURE SEARCH STRATEGY 
The electronic database, PubMed, was used to search for relevant literature. Literature was 
reviewed up until January 2019. Only English and full text articles were included. All study 
types were included, although all the studies reviewed were retrospective cohort analyses. 
Literature was also searched for manually by screening the references of studies identified in 
the electronic search. The following search terms were used for the primary objective: 
• Resectional surgery 
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• Drug-resistant tuberculosis 
• XDR-TB 
• Africa 
The following search terms were used for the secondary objective: 
• PET-CT 
• Prognostic value 
• Drug resistant tuberculosis 
• XDR-TB 
SUMMARY OF FINDINGS 
Primary aim(s) 
Outcomes for resectional surgery for multidrug-resistant tuberculosis 
Two frequently cited and accepted bodies of work define outcomes for TB therapy and are 
used in many of the studies included in this review. Outcomes were reported in the studies 
according to standardised definitions by Laserson or the World Health Organisation, which 
are comparable (14, 19, 20). Successful treatment outcomes include cure and treatment 
completion, whilst unsuccessful treatment outcome refer to death, defaulting and treatment 
failure. These categories are further detailed below. 
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Marrone et. al. published the first large international systematic review and meta-analysis of 
patient outcomes after resectional lung surgery for all types of drug-resistant tuberculosis in 
2013, including a total of 47 studies (21). Due to the nature of this illness and the usual 
indications for surgery, there are no randomised controlled studies in this field, and all 
evidence is drawn from observational studies. Collated findings from 24 comparative studies 
showed that those who received medical therapy and adjunctive resectional surgery had 
better overall outcomes than those who had medical therapy alone (OR 2.24, 95% CI 
1.68-2.97). A total of 706 patients who underwent surgical resection for drug-resistant TB 
were described by Marrone et. al. in these 24 papers, but as is the case in many studies, 
patients with all forms of drug-resistant TB were combined in the meta-analyses, and it is 
often difficult to isolate the results in pre- and XDR-TB patients alone. The vast majority 
(21/24) of comparative studies reported outcomes in MDR-TB patients. In the remaining 
(3/24) comparative studies focussing on  XDR-TB  patients,  the  outcome  benefits  for 
surgical  resection  seemed  even  more pronounced, but we are cautious that fewer 
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absolute numbers may lead to over-powering of results in these smaller groups. In the 23 
single-arm studies included in the Marrone et. al. meta-analysis, they found overwhelming 
positive outcomes following surgery. They found that 92% (95% CI 88.1-95) and 87% (95% 
CI 83-91) of patients had successful short and long term treatment outcomes respectively. 
They defined short-term as 30 days post-operatively, and long term outcomes were 
measured at 12 months. This long term follow-up was extremely heterogeneous between 
studies, with a mean of 40 months, but starting from as little as 12 months. Notably only 2 of 
the 23 studies describe XDR-TB patients alone, with the other 23 studies describing either 
MDR-TB or a combination of all forms of drug-resistance. In addition to improved overall 
outcomes in the surgical groups, there was also a favourable association between surgical 
resection and all-cause mortality in all forms of drug-resistant TB. 
Very little could be deduced about specific characteristics regarding patient demographics, 
treatment regimens, surgical techniques used and duration of follow up, as studies were 
markedly varied and heterogenous in the Marrone et. al. review. Interestingly, HIV status was 
not described in relation to patient outcomes in this large meta-analysis. It was noted that in 
all the studies included, the main indication for surgical intervention was failure of medical 
therapy, with only a small minority being performed for other indications. 
In the more recent systematic review by Harris et. al. in 2016, results were largely 
comparable to the Marrone paper (22). Again, all studies were observational and included a 
combination of MDR- and XDR patients. In the 14 primary review articles, they reported 
successful outcomes in 81.9% of the surgical group, as compared to 59.7% in the non-
surgical groups with an odds ratio of 2.62 (95% CI 1.94-3.54) (23). They did note that loss to 
follow-up was greater in the medical group, which may have negatively biased their findings. 
This recent review also comments on the introduction of new agents into the armamentarium 
against drug-resistant TB, specifically bedaquiline and delamanid, acknowledging the 
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positive impact they have made on the medical management of this disease (4, 6). Although 
the positive impact of these new drugs is highlighted, it is also reiterated that the cure rate for 
drug-resistant TB still remain far below those for drug-sensitive TB, and that the role for 
surgery is not negated. The role of these newer agents in surgical patients was not reviewed 
in these large meta-analyses. 
Although there are discrepancies in the degrees of resistance profile ranging from MDR- to 
XDR-TB, these systematic reviews certainly seem to give strength to the widely held opinion 
that surgical resection improves outcomes for patients with drug resistant TB. 
Notably, a very recent South African paper published in May 2020 has shown drastically 
improved outcomes for MDR-TB treatment failure and XDR-TB patients using medical 
therapy alone, as compared to many historical cohorts (24). The Nix-TB trial included 109 
patients with DR-TB (65% XDR-TB, 35% MDR-TB). They used a novel treatment regimen 
comprising bedaquiline, linezolid and pretomanid for 26 or 39 weeks, depending on 
treatment response. This treatment duration is far shorter than the minimum standard 
duration of treatment for DR-TB being used in most other studies, which is greater than 12 
months. At 6 months after the end of the treatment period, 90% of patients had a positive 
outcome, which is far in excess of anything shown in previous DR-TB studies. In fact, this 
treatment success rate is one of the first in the literature that rivals that of drug-sensitive TB. 
It is prudent to note that this trial is ongoing and durable results proving treatment success 
at 24 months are yet to be shown. This study was based at 3 small centres in South Africa 
and is not the current national standard of care for DR-TB, making it difficult to accurately 
gauge the true national treatment success rates for DR-TB in this era of new and developing 
regimens. If these positive outcomes can be shown to be sustained and these drugs become 
widely available, the face of DR-TB may dramatically change for the better. The possibility of 
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achieving such high treatments success rates for DR-TB in the order of 90% will challenge 
the utility for surgical resection in such cases. The question remains, whether like almost all 
other classes of anti-tuberculous drugs, resistance will develop to these newer agents over 
time as they become more widely available and surgery may again feature as an important 
tool in the armamentarium against DR-TB, despite these promising results.  
There was only one study by Borisov et. al. that evaluated the outcomes of patients with 
drug- resistant TB treated specifically with bedaquiline-containing regimens who underwent 
adjuvant surgical resection (25). This was a retrospective review and included 55 surgical 
patients from 9 countries. In this cohort, the majority of cases (90%) had pre-XDR or XDR-
TB, with only a small minority having MDR-TB. Only 5 cases were new TB cases with 52/55 
having had previous drug-resistant TB. The indications for surgery were in keeping with the 
accepted criteria as described by Iseman et. al, with 50% of this cohort having persistent 
sputum culture- positivity (12). The median number of drugs prescribed was 5 and 6 pre- and 
post-operatively. Bedaquiline was initiated in most patients (33/55, 60%) as part of the post-
operative regimen. In the remaining cases, the bedaquiline course was initiated prior to 
surgery and completed post-surgically. Treatment success was achieved in 69% of patients 
(65% cured and 4% completed). There was a 20% treatment failure rate, but no reported 
mortalities. There was no significant difference in outcomes between the pre-operative and 
post-operative bedaquiline groups. Only 5% of patients included were HIV positive, but 
results were not stratified by HIV status. The duration of the follow-up period in this study 
was not clear and was heterogenous amongst the centres. This study deduced that the 
combination of surgery and bedaquiline was likely responsible for an additional 40% 
bacterial conversion from baseline. They also state that although the overall treatment 
success (69%) was lower than in the previous meta-analyses (80-90%), there was a far 
greater proportion of patients with pre- XDR and XDR-TB than in these large reviews with 
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predominantly MDR patients (21, 22, 25). Limiting factors in this review are the small patient 
numbers and the lack of clarity regarding follow-up period, but the overall impression is that 
in specifically selected patients, the combination of bedaquiline therapy and surgery may 
produce positive outcomes in the majority of patients. 
Smaller single review studies including sub-analyses of pre-XDR and XDR-TB were also 
informative, but again absolute numbers of patients were relatively small, and firm 
conclusions are difficult to extrapolate. 
One such observational study from Seoul evaluated outcomes of 26 XDR- and 46 MDR-TB 
patients and showed overwhelmingly positive results for patients following surgical resection 
(23). The majority of patients underwent surgery for medical failure (71%), and had received 
medical therapy for a minimum of 3 months. The other 24% of patients were operated on 
after being deemed to have ‘high risk of relapse’ due to persistent localised cavitatory 
disease. Unfortunately, many of the results reported in this study combined patients with 
MDR- and XDR-TB. Successful outcomes, however, were reported separately for the MDR- 
and XDR- TB groups and was found to be 85% in the XDR-TB group. This was not 
significantly different from the MDR-TB group. 
Another study from KwaZulu-Natal showed promising results with adjunctive surgical therapy 
and is included in this review as it is contextually relevant to South Africa (26). The group 
aimed to look into surgical resection as part of the management of XDR-TB as medical 
therapy alone was proven to be insufficient, with 73% mortality at 5 years (7). A total of 10 
XDR-TB patients were reviewed for surgical intervention, but 6 were excluded due to 
bilateral extensive cavitatory disease, as is widely practiced. This left only 4 patients to 
undergo adjunctive surgical resection. All 4 patients had failure of medical treatment as the 
indication for surgery. The successful outcome rate in this small cohort was 100%, with all 4 
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patients being cured. They also reported no peri-operative morbidity. Given the very small 
number of patients in this report, it is difficult to regard their positive findings as anything 
beyond anecdotal for this particular XDR-TB cohort. 
Two particular studies showed results markedly deviating from those reviewed above; with 
much poorer overall outcomes in their surgical cohorts (27, 28). A European study based in 
Latvia retrospectively reported surgical outcomes in 17 patients from 2000-2003 (27). 
Although XDR was only defined in 2006, these patients were found to meet criteria for XDR- 
TB based on drug-sensitivity testing (DST). The main indication for surgery remained in line 
with other reports, with failed medical therapy being the indication in 15/17 patients, and only 
one patient having surgery for presumed high risk of relapse due to cavitatory disease and 
one for emergency resection for pulmonary haemorrhage. At the time of surgical 
intervention, 94% of patients were sputum culture positive. Although 5 patients were reported 
to have bilateral cavitatory disease based on chest radiographs, they were still eligible for 
surgery, which is not common practice in other centres. The Latvian group found that only 
47% of patients were cured, while the rest had unsuccessful outcomes, with 47% having 
treatment failure and 6% death. Despite their much lower treatment success rates than in 
other studies, the success rate of 47% still exceeded the background cure rates for medical 
therapy alone for XDR-TB across other parts of Europe during the same time. 
The second study showing poor outcomes was conducted in Beijing, China and followed 
patients with DR-TB from 1992-2012 (28). They were able to report findings on 21 patients in 
total after following them up for 3 years. Only a third of these patients had XDR-TB, with the 
reminder having MDR-TB. The exact indications for surgical intervention were not well 
detailed in this study and the breakdown was unclear. Overall, only 38% of patients had 
favourable outcomes after 3 years. The small XDR group showed far worse outcomes than 
the MDR group, with only 14% successful outcomes as compared to 50% in the MDR group. 
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In the subset of patients who had negative outcomes, the surgical complication rate was also 
high, with 46% of patients experiencing septic or fistulizing post-post-operative 
complications. The overall mortality rate in this Beijing cohort was 24%, which was much 
higher than in other groups, and not in keeping with the large meta-analyses conducted by 
Marrone et. al. and Harris et. al. It is unclear why the success rate was much lower in this 
paper than in many other international centres, but the lack of clarity surrounding patient 
selection and inclusion criteria for surgery does raise the concern of whether this may have 
played an important role. 
Optimal timing of surgical intervention 
The optimal timing for surgical intervention still remains unclear after reviewing the recent 
literature. Two opposing theories exist and are raised in the large meta-analyses by Marrone 
et. al. and Harris et. al. again in 2016. Once school of thought is that early surgical 
intervention within 4 months potentially optimises the chances of cure. The rationale behind 
this is that patients will have less morbidity with non-advanced tuberculous disease and 
would be in better physiological condition for surgery if they were not left on failing medical 
regimens for a protracted time. It was also postulated that the prolongation of failing medical 
therapy may lead to higher degrees of drug-resistance. The other school of thought is that 
longer exposure to anti-tuberculous therapy allows for time to optimise nutritional status and 
other medical co- morbidities prior to surgery and may produce better outcomes. There is no 
direct evidence to support or refute either of these strategies and the timing of surgery tends 
to be in line with institutional practices at various centres. It also seemed that the timing of 
surgical intervention after medical therapy varied vastly between centres, and also often 
within centres themselves, ranging from 2.3 months to more than 12 (23, 26, 27). 
In the bedaquiline-regimen study, the median (IQR) time to surgical intervention was 8 (5-13) 
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months on a regimen with an average of 5 presumed effective drugs (25). No patients were 
on delaminid and bedaquiline concurrently. Notably in this study, only half the patients were 
sputum culture-positive at the time of surgical intervention, which was lower than in the other 
studies included in this review (21). The overall success rate in this study was 69%. It is 
unclear how sputum status at the time of surgery may have affected overall treatment 
outcomes in this particular study. It is considered that pre-operative used of bedaquiline may 
have reduced the need for surgery in some patients, but their data could not support this 
theory. 
In the Seoul cohort, the median time to surgery was approximately 5.2 months on effective 
medical therapy (23). Effective therapy was considered 3 drugs with proven sensitivity, or in 
cases without proven sensitivity, drugs in line with accepted XDR-TB regimens. This timing 
for surgery was adopted to attempt to remain in line with the WHO recommendation to 
consider surgery after failed medical therapy after 3-4 months (27). In this group, 85% of 
XDR-TB patients has successful surgical outcomes. 
In the Latvian study, the median duration of pre-operative medical therapy was 12 months, 
which was significantly longer than in other studies (28). They did have much lower success 
rates with only 47% cure as compared to 85%, but the exact reason for this difference is 
unclear, and could not directly be attributed to the longer pre-operative medical therapy and 
delayed approach to surgical resection. In the exceptionally small cohort of patients from 
KwaZulu-Natal, the pre-operative medical therapy ranged from 2.3-10.8 months with 100% 
successful outcomes reported, which again does not shed light the optimal timing for surgical 
intervention as these patients has both very early and very late intervention. 
The optimal timing for surgery remains to be determined, given the conflicting findings from 
many studies and lack of clarity in the 2 large meta-analyses. 
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Post-operative chemotherapy duration 
As with the timing of surgery, the duration of post-operative chemotherapy is also unclear 
from the literature. Marrone et. al. comment that a minimum of 12 months of post-operative 
chemotherapy is required to increase the likelihood of cure, but many studies included in the 
meta-analyses did not specify the duration the of post-operative chemotherapy and this was 
not formally analysed (21). They, along with Harris et. al. recommend 12-24 months of post- 
operative chemotherapy as a standard approach, but could not elaborate further (21, 22). 
In the Kwa-Zulu Natal group, post-operative chemotherapy was continued for 14.5-15.8 
months in their small subset of 5 patients, all of whom has successful outcomes. In the 
Latvian study, the mean duration of post-operative chemotherapy was 14.5 months, but their 
overall success rate in the surgical group was only 47%. 
The median (IQR) duration of post-operative anti-tuberculous therapy in the bedaquline- 
regimen study was shorter than any of the previously described studies and was only 10 (7- 
14) months (25). The majority of patients (60%) in this study were treated with bedaquiline 
as part of their post-operative management. The individual effect of this particular drug on 
treatment outcomes was not quantified in the study, but it was noted that this effect should 
probably be defined further. 
It is clear that there are many determinants to successful outcomes and that the duration of 
post-operative chemotherapy is not the only factor at play. Having said this, many of the 
studies tended to continue treatment for a period of 12-24 months and classified patients as 
cured once they remained sputum culture-negative for 12 consecutive months on treatment. 
The duration of treatment after this point tended to be more highly variable. 
Factors influencing treatment outcomes 
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The durations of both pre- and post-post-operative medical therapy and their potential 
influence on treatment outcomes have been described above. 
In the large meta-analyses, little could be deduced about other specific factors that 
influenced outcomes either positively or negatively, as studies were extremely heterogenous, 
and details recorded in studies were not standardised. We felt that HIV may be a relevant 
factor, but this was not described extensively in the literature. Marrone et. al. did not explicitly 
report the HIV prevalence, nor was this analysed as a potential mediator of outcomes. All 
patients in the Latvian surgical cohort were tested for HIV, but none were found to be HIV-
infected. Again in the small surgical cohort in Kwa-Zulu Natal, only 1 of the 5 patients was 
HIV-infected and was reported to have a suppressed viral load on antiretroviral therapy 
(ART), making it difficult to draw any conclusions as to the role HIV might play in determining 
patient outcomes. In this particular study, inclusion criteria stipulated that HIV-infected 
patients must be on established ART and meet criteria for viral suppression. Two different 
South African studies followed XRD- TB patients treated only with medical therapy and found 
culture conversion rates from 11-19% (2, 7). Both these studies included patients with HIV 
and neither showed any significant difference in treatment outcomes. Both ART-naive and 
ART-established patients were included in these studies.  The Nix-TB trial, looking at 
outcomes for DR-TB patients with medical management alone, found no significant 
differences between HIV infected (51%) and HIV non-infected patients (24).  All HIV positive 
patients in this trial were managed with concomitant TB and ART therapy. With limited 
available robust data, it remains unclear as to whether HIV co-infection, clinical staging or 
treatment with ART in XDR-TB plays a significant modulatory role in either medical or 
surgically managed patients. 
The number of drugs used is also widely thought to influence outcomes. It is important to 
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differentiate between the absolute number of anti-tuberculous drugs used and the number of 
effective anti-tuberculous drugs with proven sensitivity. The effect of the number of total and 
effective number of drugs was difficult to determine, as this varied both between and within 
studies. In the Marrone et. al. meta-analysis, the mean number of drugs in a regimen was 
5.3 and 4.4 in the comparative and single-arm groups respectively In both groups, p-values 
showed that no significant difference could be determined in outcomes when comparing 
patients on regimens of 5 or more drugs to those on less than 5 drugs. These drug regimens 
were not all stratified according to known number of effective drugs, as extended sensitivities 
were not available in many reviews, and no conclusion can be drawn as to whether a 
minimum number of effective drugs may play a positive role. The current WHO guidelines 
suggest a minimum of 5 effective agents based on drug-susceptibility testing (DST) in 
regimens for drug- resistant TB (19, 29). A major barrier in determining resistance profiling 
and DST is the lack of laboratory resources and other infrastructure in developing and third 
world countries (1). Another issue is the long delay required for full DST to be conducted, as 
this requires prolonged incubation and culture time. This seemed to be evident in studies 
published from Latvia, South Africa and South Korea, where none of the studies were able to 
accurately report on the number of effective drugs as determined by DST. The NIX study 
used a unique trial regimen of 3 effective anti-tuberculous drugs (linezolid, bedaquiline, and 
pretomanid) and was one of the few studies where drug levels and minimum inhibitory 
concentrations were determined in a large proportion of patients (52%) to ensure treatment 
efficacy (24). The mean numbers of drugs used varied between 3-7 drugs in the above-
included studies with no correlations between the number of drugs and outcomes being 
determined.  
According to the recommendation by WHO, all patients undergoing surgical resection must 
be deemed to have sufficient cardiopulmonary reserve post-surgery. This was stipulated in 
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most studies included and was determined by a multi-disciplinary group. This selection bias 
of only including patients deemed to have better physiological reserve to withstand surgery 
has been highlighted in a number of papers. It is acknowledged that this bias may sway 
benefit in the favour of surgery as these patients may have less extensive disease and 
therefore a higher likelihood of treatment success. 
Secondary Aim 
Role of PET/CT as predictor of outcomes 
In all the studies included above to report treatment outcomes, none included PET/CT as a 
routine pre-operative investigation, nor did they comment on its role as a potential modulator 
for outcomes. Thus far, to the best of our knowledge, there is no robust data on the use of 
PET/CT as a tool to predict treatment outcomes in either drug-sensitive or drug-resistant TB. 
This is regardless of whether patients are treated medically only or with adjunctive surgery. 
One South African paper in 2017 did evaluate the role of radiology alone in predicting 
treatment outcomes in patients who underwent adjunctive lung resection for drug-resistant 
TB in a high HIV-burden area (18). They proposed that although pulmonary nodules have a 
lower burden of disease and bacilli than cavities, they may represent active infection and 
perhaps should be resected to reduce overall bacillary load. It was acknowledged that this 
was not always possible due to anatomical distribution and/or residual pulmonary reserve. 
They described the association between peri-operative pulmonary nodules, as seen on plain 
chest radiograph and CT, and sputum culture conversion in 47 HIV-positive and negative 
patients. Chest radiography (performed a week prior to surgery) and high-resolution CT 
(performed 2 months prior to surgery) showed that a total of 60% of patients had nodular 
disease pre- operatively. Both modalities showed that the majority of patients had nodules in 
the upper lobes (50% and 61% respectively). The distribution of lesions was similar in both 
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modalities of imaging, and in HIV-positive (57%) and negative groups. Most patients who 
underwent surgery were sputum culture-negative at the time of surgery (66%) which was not 
associated in any way with the presence of pulmonary nodules. Post-operative chest 
radiography and sputum culture were performed at 6 weeks after resection. Nodules were 
either new or residual from the non-resected tissue. No follow up CT imaging was 
performed. Sputum cultures were performed up until 6 months. In keeping with WHO 
guidelines, successful outcome was defined as persistently negative culture following 
resection (17). This local study showed no associations between composite sputum culture 
outcomes at 6 months and the presence of nodules, either pre-operatively (p=0.73) or post-
operatively (p=0.52). There was also no difference shown in the HIV infected and non-
infected groups. Although no association was found in this small study, the investigators did 
comment that the use of 18-FDG PET/CT may be a useful tool to evaluate the activity of 
such nodules to better characterise disease activity. 
In another paper from our setting, it is also stated that PET/CT may be included in the work 
up of the potential surgical candidates to confirm contralateral metabolically active disease in 
the form of nodal or parenchymal disease (1). They also postulate that this may be useful to 
determine disease activity in patients with radiological changes secondary to prior TB 
infection. This theory is supported by current literature, which suggests that PET/CT is a 
sensitive tool to detect TB and differentiate between active and previous tuberculous 
infection, especially in cases with cavitatory disease (16). It has also been shown that PET/
CT is superior to CT or MRI alone in detecting active tuberculous disease (17). There is no 
information to guide whether the burden of disease at the start of treatment, as detected by 
PET/CT, predicts outcomes in anyway. Furthermore, there is no data to guide whether the 
burden of disease, in the form of cavities, nodes, parenchyma infiltrates or other radio-tracer 
measurements at the start of treatment, should or can be used to select whether patients 
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should undergo surgical management or not. The role of PET/CT remains unclear in guiding 
clinical practice in this field. 
Gaps and direction for our study 
We aim to describe the outcomes of our surgical XDR-cohort and compare our results to 
those reported in various other centres, taking note to try and account for variances that may 
be observed. We acknowledge that our study will take place in a developing country context 
and our results may be more aligned with those from similar contextual backgrounds. We 
also aim to describe any patient or treatment characteristics that may significantly affect 
outcomes. We would like to describe the role of HIV co-infection in our cohort, given the high 
burden of this disease in South Africa and determine whether this plays a bigger role than in 
other reports where prevalence is lower. 
The value of PET/CT as a non-invasive clinical investigation to assist with patient selection 
for surgery will also be explored in our study. We aim to determine whether any specific 
radiological or metabolic activity measurements may be useful markers to guide clinical 
practice, given that this question remains unanswered in current literature. 
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MANUSCRIPT: 
Outcomes of patients undergoing lung resection for drug-resistant TB and the 
prognostic significance of pre-operative positron emission tomography/computed 
tomography (PET/CT) in predicting treatment failure 
INTRODUCTION 
Multi drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are public 
health emergencies in South Africa, with limited pharmacological options for cure. The 
overall treatment outcomes of pre-XDR and XDR-TB in particular are far from satisfactory(1). 
A retrospective study from our setting (in the era before linezolid, bedaquiline and delaminid) 
showed that only 19% of patients culture-converted on the pharmacotherapy available at the 
time(2). In the absence of effective drug regimens, and in appropriate patients, surgery with 
resection of involved lung tissue has been employed in selected patients as a form of 
adjunctive treatment in DR-TB. The rationale behind surgery for TB is to dramatically reduce 
the overall organism burden in the lung (while simultaneously removing the sites of high 
concentrations of drug resistant bacilli) by excising thick-walled cavitatory lesions and areas 




M.tb organisms(3). This “debulking” 
hopes to enhance the sterilizing properties of post-surgical chemotherapy and to increase 
the likelihood of treatment success(4, 5). 
Many comparison studies and a systematic review (which included patient-level data from 
over 5000 participants) have shown improved outcomes in patients who undergo lung 
resection for DR-TB(6). The treatment benefit seems to be more pronounced in patients with 
a higher resistance profile, supporting the widely-held view that surgery as a therapeutic 
option becomes even more attractive as effective chemotherapeutic options dwindle. 
However, there are no data from under-resourced, high HIV-burden settings like South 
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Africa. Little is known about factors that may influence patient selection and that may be 
associated with treatment outcomes. 
Active tuberculosis infection (including asymptomatic and extrapulmonary disease) may be 
detected with 18-fluorodeoxyglucose (FDG) positron emission tomography/computed 
tomography (PET/CT)(7). PET/CT is a non-invasive imaging method that may give additional 
information about tuberculous disease status, including parenchymal as well as nodal 
metabolic activity. As patients with drug-resistant tuberculosis usually have been treated for 
TB in the past, PET/CT may distinguish active tuberculous lesions from the fibrotic 
consequences of previous episodes of healed TB. 
In our centre, current practice is to usually exclude patients where lung resection would still 
leave a FDG-avid cavity or cavities in the contralateral lung (in the case of pneumonectomy) 
or remaining ipsilateral lung lobe or lobes (in the case of lobectomy). The rationale for this is 
that cavities have exponentially more actively replicating bacilli than other parenchymal 
lesions and are penetrated poorly by antituberculous drugs, substantially reducing the 
chance of a postoperative cure with antituberculous therapy. The role of areas of FDG-avid 
nodular disease or consolidation (which contain exponentially less organisms) on treatment 
outcomes is unknown. 
We hypothesised that patients undergoing lung resection would have improved outcomes 
compared to historical cohorts in whom surgery was not offered. We also hypothesised that 
PET activity distant from the site of resection, either cavitatory or non-cavitatory parenchymal 
change in the contralateral lung or adjacent lung lobe or in the mediastinum, measured 
preoperatively before surgery, would influence treatment outcomes. 
METHODS 
Study design and oversight 
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We conducted a single-centre, retrospective study of patients undergoing lung resection in 
patients with DR-TB in Cape Town, South Africa. The study was approved by the local ethics 
committee. The study is reported in accordance with the STROBE statement for 
observational trials(8). 
Study population 
All DR-TB patients undergoing resectional surgery at Groote Schuur Hospital (GSH) 
between July 2010 and December 2016 were enrolled in a registry. GSH is a large 
government-funded teaching hospital affiliated to the University of Cape Town, South Africa, 
serving a population of approximately 3 million largely underprivileged people in Cape Town 
and the surrounding informal settlements. Patients were offered resectional surgery based 
on conventional physiological and radiological assessments of operability and resectability, 
as determined by a multidisciplinary team (pulmonologists, thoracic surgeons, nuclear 
medicine physicians and radiologists). 
Study procedures 
Socio-demographic and clinical data on our patients was extracted from the XDR-registry 
using the UCT Research Ethics Committee reference #038/2008. The degree of drug 
resistance was determined by the National Health Laboratory Services (NHLS) using the 
BACTEC MGIT 960 system(9) and line probe assays (MTBDRplus, Hain Lifesciences, 
Nehren, Germany). A subset of patients had extended drug sensitivity determined pre- 
operatively by whole genome sequencing (WGS) as part of a related pharmacokinetics study 
conducted at the same centre(10). Sputum samples were collected and cultured from these 
patients either on the day of or the day prior to resectional surgery. Pre-operative drug 
regimens were documented as part of the work-up for surgery and for enrolment into the 





A subset of patients included in the registry underwent PET/CT as part of the pre-operative 
workup prior to their surgical resection. PET/CT was performed to aid surgical decision-
making in cases where there was radiological disease in the contralateral lung (in the case of 
proposed pneumonectomy) or remaining ipsilateral lung lobe or lobes (in the case of 
proposed lobectomy), or if there was contralateral intrathoracic lymphadenopathy. 18-FDG 
was used as the nuclear tracer. Patients were imaged using the GEMINI TF Big Bore 
PHILIPS whole-body scanner (Philips Healthcare, Eindhoven, Netherlands), and were 
prepared and imaged in accordance with the FDG PET/CT EANM guidelines for tumour 
imaging: version 2.0(11). Images were viewed with Hermes Hybrid Viewer PDR v.2.2C.21 
and interpreted by two independent nuclear medicine physicians and a radiologist. 
In the absence of a standardised method of quantifying tuberculous disease burden in PET/
CT, various measures of 18-FDG-avidity (visual score, highest SUV, mean SUV, and 
volumetric determinations) were measured(12). Regions of interest (ROIs) were defined as 
areas of increased 18-FDG uptake within the remaining lung parenchyma. These regions 
were drawn semi-automatically on transaxial slices, with a standard uptake value (SUV) 
threshold of 2.5 being used for automatic edge detection. Standard uptake values were 
calculated using the following formula: SUV w = A × W/D × 1000 g/c (where SUV w = 
normalization to body weight, A = activity concentration in Becquerel/cubic centimeters (Bq/
cm
3
), W = patient weight in kg and D= injected dose in Bq decay corrected to the time of 
injection. The following parameters were recorded in regions of interest (ROIs) in the 
residual lung tissue after resectional surgery: SUV max, SUV mean, residual metabolic 
disease volume (MDV) and residual  total  disease  glycolysis (TDG).  Presence  or  absence 
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of  cavities,  nodules  or 
consolidation in remaining lung parenchyma was also documented. A visual score ranging 
from 0 to 4 of the residual metabolically active disease was also performed, as follows: 0 = 
no visible uptake; 1 = uptake lower than mediastinal blood pool activity; 2 = uptake 
comparable to mediastinal blood pool activity; 3 = uptake greater than mediastinal blood pool 
activity, and; 4 = uptake significantly greater (3 times higher) than mediastinal blood pool 
activity. 
Follow up 
Study patients were followed for two years post-operatively. During this time, sputum culture 
status as well as mortality was evaluated at 6-monthly intervals. Many patients followed up 
and submitted sputum samples at their local clinics after discharge from GSH, and their data 
was collected by a field nurse who visited these clinics as part of this study. Patients from 
other provinces were tracked with the assistance of doctors at TB clinics at these centres. 
Post-operative treatment regimens were also documented. 
Outcomes 
The primary measure was the outcome of patients undergoing lung resection for DR-TB at 
24 months after surgery, using the WHO treatment outcome definitions(13). Treatment 
outcome was considered a “success” if it resulted in completion or cure, and a “failure” if 
treatment failed (persistent sputum culture positivity), the patient died, or the patient 
defaulted or was lost to follow up. Secondary measures included clinical predictors of 
treatment failure, sputum conversion, and quantitative PET/CT measures associated with 
unsuccessful outcomes. 
Statistical analyses 
Continuous variables were presented as means with standard deviation (for normally 
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distributed data) and medians with interquartile range (for non-normally distributed data), and 
categorical data as frequencies and percentages. Normally and non-normally distributed 
data was compared between groups using students t-test or Wilcoxon rank sum test, 
respectively. Categorical data was analysed using the Chi-squared test or Fishers exact test 
depending on their distributions. We analysed associations between outcome (composite 
treatment failure) and clinically important variables using univariate and multivariate logistic 
regression. Different measures of disease burden using 18-FDG uptake were also explored 
in univariate and multivariate analysis. Statistical analyses were performed using GraphPad 




Between July 2010 and December 2016, 35 patients with DR-TB underwent lung resection 
at our institution (table 1). The number of patients with XDR-TB, pre-XDR-TB and MDR-TB 
was 27 (77%), 5 (14%) and 3 (9%), respectively. Twenty patients (57%) had previously been 
treated for DR-TB, and 29 (83%) were culture-positive at the time of surgery. Nine patients 
(26%) were HIV positive, with a median (IQR) CD4 count of 407 (274-435); all were on 
antiretroviral therapy. The surgical procedure was a pneumonectomy in 20 (57%) of cases, 
and a lobectomy in 15 (43%) (one patient underwent a completion pneumonectomy after 
initial lobectomy). Only about a quarter of patients had exposure to bedaquiline and linezolid 
(23% and 29%, respectively); these patients were all recruited in the latter part of the study 




At 24 months after surgery, 15 (43%) of patients were considered programmatically cured, 5 
(14%) had failed treatment, and 3 (9%) had defaulted or were lost to follow-up. All-cause 
mortality at 24 months was 10/37 (27%). There were 2 (5%) early post-operative deaths 
(within 30 days) and 6 (16%) died by six months. Univariate peri-operative predictors of 
treatment failure were HIV positivity, degree of drug resistance (XDR-TB vs. pre-XDR-TB 
and MDR-TB), and post-operative bedaquiline and linezolid use; only degree of drug 
resistance and bedaquiline use were significant on multivariable analysis (table 2). Sputum 
culture conversion, if it occurred and was durable. was most likely to occur early: 12/35 
(35%) culture- converted by six months (figure 1). Sputum culture conversion at 6 months 
was a significant post-operative measure associated with successful outcome; however, this 
became non- significant if corrected for degree of resistance. In a multivariable analysis, only 
XDR status (adjusted OR 0.17, 95% CI 0.03-0.87, p=0.03, and the use of post-operative 
bedaquiline (adjusted OR 28.5, 95% CI 2.40-339.0, p<0·01) were associated with sputum 
conversion. 
Pre-operative PET/CT 
PET/CT was performed in 25 (71%) patients; in the remaining 10 (29%), the absence of 
intrathoracic lymphadenopathy or any radiological disease outside of the planned anatomical 
resection on plain CT was deemed sufficient evidence by the MDT to proceed without PET. 
The commonest FDG-avid radiological abnormality seen was contralateral nodularity (85%), 
followed by intrathoracic lymphadenopathy (32%). There was no difference in either the 
burden of FDG-avid radiological disease (cavities, nodules, consolidation or extrapulmonary 
disease), visual scores, or quantitative estimates of FDG-avidity [either absolute (SUV max 
and peak, or volumetric (MDV and TDG)] between patients with treatment failure or success 
(table 3). In multivariable Cox proportional analysis, there was no PET/CT value associated 
with shorter time to treatment failure (table 4). Receiver operating characteristic curve 
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analysis showed that sensitivity and specificity for treatment failure of all PET/CT measures 
of non- resected disease burden for treatment outcome was poor (figure 2). 
DISCUSSION 
This study, which adds to the limited data on surgical outcomes for DR-TB in high HIV 
burden settings and sub-Saharan Africa and, to our knowledge, the first to examine the role 
of PET- CT in surgery for DR-TB, has two main findings. First, it demonstrates that 
resectional surgery for XDR-TB in combination with available chemotherapy at the time 
resulted in a cure in ~ 50% of patients. The main risk factor for poor outcome was the degree 
of drug resistance. Second, treatment outcomes were not modified by the presence of PET-
positive disease, regardless of its radiological type. This finding supports the rationale that 
adjunctive surgery for TB is primarily a debulking procedure and suggests that factors other 
than the burden of FDG-avid disease in the non-resected lung are associated with treatment 
outcome. Thirdly, it shows – as with patients treated with chemotherapy alone – that sputum 
conversion is most likely in the first six months, and that this is a predictor of durable 
outcome. 
The outcomes reported in this study are considerably worse than those in previous reports of 
surgery for DR-TB from other settings and eras (6, 14-19) during which bedaquiline and 
linezolid were not widely available; however, our cohort differs in that the degree of drug 
resistance and the prevalence of culture positivity at the time of surgery was much higher 
than in those studies. Our outcomes are better than those of historical cohorts of XDR 
patients treated with chemotherapy alone (20), but worse than those of recent cohorts 
treated with bedaquiline, linezolid and other newer agents, with or without surgery (21-23, 
24). The implication is that treatment outcomes are highly dependent on the efficacy of pre- 
and post-surgical chemotherapy, which has increased with the introduction of linezolid and 
bedaquiline to the DR-TB regimen. It is notable, however, that all patients treated with a 
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bedaquiline-containing regimen and surgery in our cohort had a successful outcome; this is 
in keeping with a recent report (22). The role for resectional surgery may evolve as success 
rates with newer bedaquiline- and linezolid-containing treatment regimens increase and 
become more widely available and accessible.  
To our knowledge, none of the previous studies of adjunctive surgery for drug-resistant 
tuberculosis have included PET/CT as a pre-operative investigation, nor are there any data 
of its use as a potential aid in surgical decision-making or as a predictor of treatment 
outcome. In the absence of a standardised method, we measured both FDG-avid intensity 
and volumetric estimations, neither of which were associated with worse outcome. Even the 
presence of contralateral cavitatory disease, with its poor drug penetration and higher 
mycobacterial burden, was not a risk factor for treatment failure. The overall implication is 
that remaining FDG-avidity, in the context of surgery planned to resect the major radiological 
burden of disease, does not influence treatment outcome in the setting of appropriate 
chemotherapy. 
Several limitations of this study deserve emphasis. First, as there was no non-operative 
group, the impact of adjunctive surgery on TB outcomes cannot be directly compared. 
Adjunctive surgery is likely to be offered to patients with better physiological status, more 
localised disease and fewer comorbidities, so there is inherent bias in such a comparison; 
randomised trials on this question are also unlikely to ever be performed. The opposite may 
also be true: in the era of more effective chemotherapy, surgery may be reserved for patients 
who are already failing complex treatment regimens, and thus have higher resistance 
patterns (and worse outcomes). Secondly, as this was not part of the clinical treatment 
protocol, data on extended drug sensitivity was only collected on a subset of patients, so the 
influence of exact number of confirmed effective drugs in the post-operative regimen could 
not be properly interrogated. Thirdly, this is data from a single centre, and our numbers were 
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small, so the influence of FDG-avid disease on outcome may have been falsely 
underestimated (type II error); nevertheless, the analyses of PET/CT data as predictors of 
outcome were all resoundingly non-significant. Lastly, the study straddled the era in which 
bedaquiline and linezolid – the two most important additions to the DR-TB treatment regimen 
in recent times – were introduced as standard-of-care in South Africa, diluting the potential 
effect of surgery alone on treatment outcomes. 
In summary, resectional surgery for DR-TB in combination with chemotherapy resulted in 
cure in less than half of the patients. Our data do not support the use of PET-CT to preselect 
patients or prognosticate about their outcome. These data inform clinical practice and 
underscore the need to support antibiotic stewardship strategies in TB-endemic settings. 
Prospective and adequately powered studies are needed to understand when to surgically 
intervene on difficult-to-treat TB cases in the era where bedaquiline and linezolid are 
available. 
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LIST OF ABBREVIATIONS 




DR Drug resistant 
DST Drug sensitivity testing
FDG FLuorodeoxyglucose
HIV Human immunodeficiency virus
MDR Multi-drug resistant 
MDV Metabolic disease volume 
MRI Magnetic resonance imaging
PET Positron emission tomography
ROC Receiver operator curve
ROI Region of interest
SUV Standard uptake volume
TB Tuberculosis
TDG Total disease glycolysis 
WHO World Health Organization 
XDR Extremely drug resistant 
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ANNEXE: 
TABLES AND FIGURES  
Table 1.  Baseline characteristics of patients undergoing lung resection for DR-TB 
Abbreviations: IQR - interquartile range; HIV - Human Immunodeficiency Virus; XDR – extensively 
drug-resistant; DR-TB – drug-resistant tuberculosis; BDQ - bedaqualine;  LZD – linezolid.   
Characteristic n=35
Age, median (IQR) 40 (28-47)
Male, n (%) 17 (49%)




Preoperative drug resistance profiles 
   XDR, n (%) 
   Pre-XDR, n (%) 




Current smokers, n (%) 15 (43%)
Previous episode of DR-TB, n (%) 20 (57%)
Sputum culture positivity at time of surgery, n (%) 29 (83%)
Capreomycin resistant, n (%) 6 (17%)
BDQ exposure pre- or post-surgery,  n (%) 8 (23%)
LZD exposure pre- or post-surgery,  n (%) 10 (29%)
Procedure 
  Pneumonectomy, n (%) 




Table 2.  Predictors of treatment failure in all patients (n=35) 










(per year increase) 35 1.03 0.97-1.10) 0.30
Male sex 
(vs. female) 35 0.27 (0.07-1.11) 0.07
HIV positive status  
(vs. negative) 9 9.33 (1.02-85.70) 0.05
Current/former smoking status 
(vs. non-smoking) 14 2.75 (0.65-11.62) 0.17
XDR status 





DR-TB treatment  
(vs. no previous treatment) 20 0.81 (0.21-3.17) 0.77
P n e u m o n e c t o m y ( v s . 
lobectomy)
22 1.24 (0.31-4.93) 0.76
Positive pre-operative sputum 
culture (vs. negative) 29 3.27 (0.51-20.93) 0.21
Post-operative bedaqualine  
(vs. no bedaqualine) 8 ** ** ** **
Post-operative linezolid  
(vs. no linezolid) 10 0.20 (0.04-0.99) 0.05
Drugs in regimen with 
confirmed sensitivity  
(per one drug increase) 35 0.86 (0.50-1.47) 0.56
Post-operative measures
Sputum culture conversion at 6 
months 35 0.10 (0.02-0.51) <0.01 0.17 
(0.02-1.38)
0.10
Sputum culture conversion at 
12 months 45 1.33 (0.41-4.29) 0.48
Abbreviations: OR = odds ratio; CI = confidence interval; HIV = human immunodeficiency 
virus; XDR-TB = extensively drug-resistant tuberculosis; MDR-TB = multidrug-resistant 
tuberculosis. 
  †  Adjusted for HIV status, XDR . 
** Unable to calculate OR as there were no treatment failures in this category.
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Table 3.   Characteristics of pre-operative 18-fluorodeoxyglucose-avid lesions as detected by positron 
emission tomography/computed tomography (PET/CT) by treatment outcome 
 p-values determined by: *Z-test; #Mann-Whitney U test 
Abbreviations: PET/CT - positron emission tomography/computed tomography; SUV – standardised 
uptake values 










  Nodularity, n (%) 
  Cavitation, n (%) 














  Nodularity, n (%) 
  Cavitation, n (%) 














  Visceral nodules, n (%) 
  Bone, n (%) 
  Intrathoracic 













PET/CT measures of activity 
  Visual, median (IQR) 
  SUV max, median (IQR) 
  SUV peak, median (IQR) 
  Metabolic Disease Volume, 
median (IQR) 






















p-values determined by: *Z-test; #Mann-Whitney U test 
Abbreviations: PET/CT - positron emission tomography/computed tomography; 
SUV – standardised uptake values.
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Table 4.  Cox model for the outcome of treatment failure based on the characteristics of pre-operative 
18-fluorodeoxyglucose-avid lesions as detected by positron emission tomography/computed 
tomography. 
Abbreviations: PET/CT - positron emission tomography/computed tomography; SUV – standardised 
uptake values; MDV – metabolic disease volume; total disease glycolysis (TDG). 







PET/CT measures of activity 
  Visual 
  SUV max 
  SUV peak 
  Metabolic Disease Volume 













Abbreviations: HR = Hazard ratio; CI = confidence interval; SUV = Standard Uptake Units   
†  Adjusted for HIV status 
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Figure 2. Receiver operating characteristic (ROC) curves for PET/CT readouts 
!  
Abbreviations: PET/CT - positron emission tomography/computed tomography; SUV – standardised 
uptake values; MDV – metabolic disease volume; total disease glycolysis (TDG). 
Receiver operating characteristic curves for each PET/CT readout using the binary predictor of 
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